This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
60
• Oral Capsule
• Oral Capsule
Acpru /Id# 264249
Grayslake, Illinois, United States
Maximum Plasma Concentration (Cmax) of ABBV-1088
Cmax of ABBV-1088
Time frame: Up to approximately 11 days
Time to Cmax (Tmax) of ABBV-1088
Tmax of ABBV-1088
Time frame: Up to approximately 11 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088
Terminal phase elimination rate constant (beta) of ABBV-1088
Time frame: Up to approximately 11 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088
Terminal phase elimination half-life of ABBV-1088
Time frame: Up to approximately 11 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088
AUCt of ABBV-1088
Time frame: Up to approximately 11 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088
AUCinf of ABBV-1088
Time frame: Up to approximately 11 days
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
Time frame: Up to Day 32
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.